Faron Announces US Food and Drug Administration and Finnish Medicines Agency Approval to Initiate Phase I/II Bexmarilimab Combination Study in Hematologic Malignancies
Faron Pharmaceuticals Ltd. (“Faron” or “Company”) Faron Announces US Food and Drug Administration and Finnish Medicines Agency Approval to Initiate Phase I/II Bexmarilimab Combination Study in Hematologic Malignancies · Phase 1 dose escalation study will evaluate the safety and tolerability of combination therapy and determine the recommended dose for Phase 2 expansion · Patient recruitment will commence in the coming weeks · Supporting pre-clinical bexmarilimab hematology data was presented at recent European Hematology Association 2022 Congress Company
In the NOMOS Glashütte production center, the parts of the in-house watch movements are manufactured like clockwork—that is to say, with high precision and always in the same way. The majority of work that goes into a NOMOS watch is done by hand, just as it was 175 years ago. But when it comes down to the micrometer, cutting-edge technology prevails.GLASHÜTTE, MAY 2022. In the Glashütte district of Schlottwitz is located the modern industrial hall, clad in local larch wood. Inside, CNC-controlled lathes and milling machines are in operation; gear cutting and wire erosion are taking place.